<DOC>
	<DOCNO>NCT00053599</DOCNO>
	<brief_summary>CLASP research study investigate safety effectiveness simvastatin ( cholesterol lower drug statin ) slow progression Alzheimer 's disease ( AD ) . Statins commonly use treat high cholesterol level , increase risk heart disease stroke .</brief_summary>
	<brief_title>Cholesterol Lowering Agent Slow Progression ( CLASP ) Alzheimer 's Disease Study</brief_title>
	<detailed_description>In early study animal human , researcher find lower cholesterol level statins seem positive impact brain function reduces risk AD . The CLASP trial test link use cholesterol lower medication slow disease progress people mild moderate Alzheimer 's disease ( AD ) . CLASP research study investigate safety effectiveness simvastatin ( cholesterol lower drug statin ) slow progression AD . The clinical trial include treatment patient mild moderate AD , objective evaluate safety efficacy simvastatin slow progression AD , measure cognitive portion AD Assessment Scale . Measures clinical global change ( ADCS-CGIC ) , mental status , functional ability , behavioral disturbance , quality life economic indicator make also . The study design randomize , double-blind , placebo-controlled , parallel group design equal randomization drug placebo . Randomization stratify blocked ensure balanced assignment within site . Sample size include 400 participant enrol approximately 40 site goal 10 15 volunteer enrol site . Study medication follow : 20 mg simvastatin match placebo give 6 week , follow 40 mg simvastatin match placebo remainder 18-month study period . Participants instructed take medication day even . Safety parameter check include adverse event , symptom checklist , vital sign , physical neurological examination , laboratory test .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Mild moderate patient AD free lifethreatening disease require lipidlowering treatment accord current guideline . NINCDS/ADRDA criterion probable AD . MiniMentalStateExam ( MMSE ) score 12 26 . Stable medical condition 3 month prior screen visit . Age great equal 50 year , upper age limit . Lives community dwelling , nursing home . Stable dos ( nonexcluded ) medication central nervous system activity 4 week prior screen visit . Physical condition acceptable study confirm medical history , physical exam , neurologic exam clinical laboratory test . Informant/study partner available willing accompany participant schedule visit complete informantbased assessment supervise administration study medication . Fluent English Spanish . Modified Hachinski less equal 4 . Exclusion criterion : Coronary heart disease ( CHD ) include angina , peripheral vascular disease include symptomatic carotid artery disease , stroke TIA , individual likely require treatment lipidlowering drug . Serious renal disease . Uncontrolled diabetes . Triglycerides great 500 mg/dL . LDLCholesterol 80 mg/dL Upper limit National Cholesterol Education Program ( NCEP ) guideline LDLCholesterol 130190 mg/dL , depend age cardiovascular risk factor . Other indication need treat lipidlowering drug . Active liver disease persistent elevation serum transaminase . Active neoplastic disease ( skin tumor melanoma exclusionary ; subject stable prostate cancer may include discretion Project Director ) . Use another investigational agent within 2 month screen visit . History clinically significant stroke . Current evidence history past 2 year seizure , head injury loss consciousness and/or immediate confusion injury . Current DSMIV criterion base diagnosis major psychiatric disorder include psychosis , major depression , bipolar disorder , alcohol substance abuse . Blindness , deafness , language difficulty disability may prevent subject participate cooperate protocol .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Cholesterol-lowering drug</keyword>
	<keyword>Mild Moderate Alzheimer disease</keyword>
</DOC>